Taiho vs. Aurobindo: LONSURF® Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Taiho Pharmaceutical Co., Ltd. et al. v. Eugia Pharma Specialties Ltd. et al. |
| Case Number | 1:19-cv-02309 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Dec 2019 – Apr 2024 4 years 3 months |
| Outcome | Settlement – Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Generic trifluridine and tipiracil tablets (15mg, 20mg) |
Case Overview
The Parties
⚖️ Plaintiff
Japan-based oncology-focused pharmaceutical company and its U.S. arm, commercializing LONSURF® (trifluridine/tipiracil tablets) in the American market.
🛡️ Defendant
Entities within the Aurobindo Pharma group, a major Indian generic pharmaceutical manufacturer with a substantial U.S. regulatory presence.
Patents at Issue
This high-stakes pharmaceutical patent infringement battle involved two U.S. patents protecting LONSURF®, a chemotherapy tablet combining trifluridine and tipiracil used in treating metastatic colorectal and gastric cancers. Patent protection in this space typically covers formulations, dosing regimens, synthesis methods, and combination ratios.
- • USRE046284E — a reissue patent, indicating the original patent underwent USPTO correction proceedings, often signaling claim scope refinement.
- • US10138223B2 — a utility patent covering compositions or methods related to the trifluridine/tipiracil combination therapy.
Developing a new oncology drug?
Check if your pharmaceutical formulation might infringe these or related patents before clinical trials.
The Verdict & Legal Analysis
Outcome
On April 3, 2024, the parties filed a Joint Stipulation of Dismissal with Prejudice pursuant to Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c). No damages award, injunction, or public licensing terms were disclosed. The retention of court jurisdiction strongly suggests the existence of a confidential settlement agreement, likely including terms governing generic market entry timing or royalty arrangements.
Verdict Cause Analysis
The case was initiated as a standard Hatch-Waxman infringement action, triggered by Eugia/Aurobindo’s ANDA filing with a Paragraph IV certification asserting that Taiho’s patents were invalid, unenforceable, or would not be infringed by their generic product. The 1,567-day duration likely allowed both parties to assess claim construction risks, validity exposure, and commercial dynamics before agreeing to terms.
Legal Significance
This dismissal carries limited direct precedential value, as no claim construction ruling, validity determination, or infringement finding was published. However, it reflects a broader pattern: the majority of Hatch-Waxman cases filed in Delaware resolve through settlement before trial, making litigation posture and settlement timing as strategically significant as substantive legal arguments.
Freedom to Operate (FTO) Analysis in Pharma
This case highlights critical IP risks in oncology drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in this therapeutic area
- See which companies are most active in oncology patents
- Understand claim construction patterns for drug formulations
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own oncology drug or formulation.
- Input your product description or chemical structures
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report for market entry
High Risk Area
Trifluridine/Tipiracil Combinations
2 Patents at Issue
Covering LONSURF® technology
Early FTO Recommended
For any similar drug combinations
✅ Key Takeaways
Dismissal with prejudice under Rule 41(a)(1)(A)(ii) reflects a negotiated resolution – analyze the retained jurisdiction clause as a signal of underlying settlement terms.
Search related Hatch-Waxman cases →Reissue patent strategy (USRE046284E) alongside standard utility patents demonstrates sophisticated pharmaceutical portfolio layering.
Explore patent family strategies →Frequently Asked Questions
The case involved U.S. Patent No. USRE046284E (a reissued patent, App. No. US14/985148) and U.S. Patent No. US10138223B2 (App. No. US15/352858), both protecting technology underlying the branded oncology product LONSURF® (trifluridine and tipiracil tablets).
The parties filed a joint stipulation of dismissal with prejudice pursuant to FRCP 41(a)(1)(A)(ii), indicating a negotiated resolution. No damages or injunction were publicly disclosed; the court retained jurisdiction to enforce the parties’ underlying agreement.
The resolution reflects the predominance of negotiated settlements in Hatch-Waxman litigation and reinforces the strategic value of reissue patents in pharmaceutical portfolio management. It offers no binding precedent on validity or infringement but informs settlement leverage dynamics in similar ANDA disputes.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Docket 1:19-cv-02309 (D. Del.)
- USPTO Patent Center — US10138223B2
- FDA Orange Book — LONSURF®
- FDA — Hatch-Waxman Act Overview
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.